

West Virginia Medicaid Drug Utilization Review Board Minutes Sep 25, 2024

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

Christopher Terpening, PharmD, PhD, Chair
David Gloss, MD, Vice Chair
C.K. Babcock, PharmD
Michael Ballow, PharmD
Chris Booth, PharmD
Scott Brown, RPh
Kate Forman, PharmD
Phillip Galapon, MD
Lester Labus, MD
Michael Lonsinger, PharmD
Mary Nemeth-Pyles, MSN, RN, CS

Members Absent:

Ernest Miller, DO

DHHR/BMS Staff:

Vicki Cunningham, PharmD, Director of Pharmacy
Gail Goodnight, PharmD
Hyla Harvey, MD, WV Medicaid Medical Director
William Hopkins, PharmD, Pharmacy Operations Manager
Lori Moles, PharmD
Priya Shah, PharmD, Drug Utilization Review Coordinator
Doug Sorvig, Data Analyst

Contract Staff:

Joe Bergondo, PharmD – Change Healthcare
Ana Bhatnagar – Change Healthcare
Eric Sears, RPh – Gainwell
Angie Wowczuk, PharmD – Rational Drug Therapy Program (RDTP)
Cory Chambliss – Acentra Health
Scott Donald, PharmD – Acentra Health
Alena Mitchell, PharmD – Acentra Health

1. INTRODUCTIONS

- a. Dr. Chris Terpening, Chair, welcomed everyone to the Board meeting at 4:02 PM (EST). The DUR Board and others introduced themselves.

2. **APPROVAL OF MINUTES FROM May 22nd, 2024 DUR BOARD MEETING**
 - a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting with no further discussion.
3. **OLD BUSINESS**
 - a. None
4. **NEW BUSINESS**
 - a. **Speakers**
 - i. None
 - b. **Updates from August 28th, 2024 P&T Committee Meeting**
 - i. Dr. Joe Bergondo presented the PDL status updates from the August 28th, 2024 P&T meeting.
 - c. **Prior Authorization Criteria.** Attachment A
 - i. **Veozah:** approved with amendments.
 1. Require a 30-day trial of one non-hormonal therapy.
 2. Patients must have tried/failed at least two alternative therapies. If a hormonal therapy cannot be tolerated two 30-day trials of non-hormonal therapies may be accepted.
 - ii. **Wegovy:** approved with amendments.
 1. Add vascular surgeon to the list of provider specialties.
 2. Clarify that criteria is for the indication of secondary prevention of cardiovascular events.
 - iii. **Winreva:** approved as presented.
 - iv. **Xolair:** approved as presented.
 - v. **Entresto:** approved as presented.
 - vi. **Ingrezza/Austedo:** approved as presented.
5. **REPORTS – 2nd Quarter of 2024**
 - a. **Gainwell Technologies Quarterly Report:** Mr. Eric Sears presented an overview of the 2024 Second Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
 - b. **Rational Drug Therapy Program:** Dr. Angela Wowczuk presented a summary of the prior authorization program for the First Quarter of 2024. Attachment C.
 - c. **Acentra Health:** Dr. Alena Mitchell presented a summary of the RDUR interventions for the Second Quarter of 2024. Attachment D.
6. **OTHER BUSINESS**
 - a. None
7. **NEXT MEETING AND ADJOURNMENT**
 - a. The meeting concluded at 5:57 PM (EST).